Repligen (NASDAQ:RGEN) Price Target Raised to $205.00

Repligen (NASDAQ:RGEN) had its target price raised by Royal Bank of Canada from $203.00 to $205.00 in a report issued on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

RGEN has been the topic of a number of other research reports. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. JPMorgan Chase & Co. increased their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday. Canaccord Genuity Group raised their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Stock Down 2.3 %

NASDAQ RGEN opened at $158.99 on Friday. Repligen has a twelve month low of $113.50 and a twelve month high of $203.13. The stock has a market cap of $8.91 billion, a PE ratio of -311.75, a PEG ratio of 4.54 and a beta of 0.99. The firm has a 50-day simple moving average of $155.22 and a 200 day simple moving average of $148.59. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. On average, research analysts forecast that Repligen will post 1.72 EPS for the current year.

Hedge Funds Weigh In On Repligen

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Signaturefd LLC increased its stake in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in Repligen during the 4th quarter worth about $29,000. Raiffeisen Bank International AG acquired a new stake in Repligen in the 4th quarter valued at about $29,000. Blue Trust Inc. raised its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the last quarter. Finally, Resources Management Corp CT ADV bought a new position in shares of Repligen in the third quarter worth about $37,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.